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Abstract
Background: The incidence of community-associated methicillin-resistant Staphylococcus aureus
(MRSA) has risen dramatically in the U.S., particularly among children. Although Streptococcus
pneumoniae colonization has been inversely associated with S. aureus colonization in unvaccinated
children, this and other risk factors for S. aureus carriage have not been assessed following
widespread use of the heptavalent pneumococcal conjugate vaccine (PCV7). Our objectives were
to (1) determine the prevalence of S. aureus and MRSA colonization in young children in the
context of widespread use of PCV7; and (2) examine risk factors for S. aureus colonization in the
post-PCV7 era, including the absence of vaccine-type S. pneumoniae colonization.
Methods: Swabs of the anterior nares (S. aureus) were obtained from children enrolled in an
ongoing study of nasopharyngeal pneumococcal colonization of healthy children in 8 Massachusetts
communities. Children 3 months to <7 years of age seen for well child or sick visits in primary care
offices from 11/03–4/04 and 10/06–4/07 were enrolled. S. aureus was identified and antibiotic
susceptibility testing was performed. Epidemiologic risk factors for S. aureus colonization were
collected from parent surveys and chart reviews, along with data on pneumococcal colonization.
Multivariate mixed model analyses were performed to identify factors associated with S. aureus
colonization.
Results: Among 1,968 children, the mean age (SD) was 2.7 (1.8) years, 32% received an antibiotic
in the past 2 months, 2% were colonized with PCV7 strains and 24% were colonized with non-
PCV7 strains. The prevalence of S. aureus colonization remained stable between 2003–04 and
2006–07 (14.6% vs. 14.1%), while MRSA colonization remained low (0.2% vs. 0.9%, p = 0.09).
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Although absence of pneumococcal colonization was not significantly associated with S. aureus
colonization, age (6–11 mo vs. ≥5 yrs, OR 0.39 [95% CI 0.24–0.64]; 1–1.99 yrs vs. ≥5 yrs, OR 0.35
[0.23–0.54]; 2–2.99 yrs vs. ≥5 yrs, OR 0.45 [0.28–0.73]; 3–3.99 yrs vs. ≥5 yrs, OR 0.53 [0.33–0.86])
and recent antibiotic use were significant predictors in multivariate models.
Conclusion: In Massachusetts, S. aureus and MRSA colonization remained stable from 2003–04 to
2006–07 among children <7 years despite widespread use of pneumococcal conjugate vaccine. S.
aureus nasal colonization varies by age and is inversely correlated with recent antibiotic use.
Background
Infections due to Staphylococcus aureus are a growing clini-
cal and public health problem in the US. [1-3]S. aureus
can cause skin and soft tissue infections, pneumonia,
bloodstream infections, and bone and joint infections in
both children and adults. [4-12] Treatment of these infec-
tions has become more difficult in recent years due to the
emergence and rapid spread of drug-resistant strains such
as methicillin-resistant S. aureus (MRSA). Most troubling
is the dramatic increase in community-associated MRSA
(CA-MRSA) infections now being reported in healthy chil-
dren and adults, but little is known about how patterns of
colonization with S. aureus in the community have
changed. [1,13-15]
Colonization of the anterior nares by S. aureus has been
shown to be associated with subsequent infection in an
individual. [16,17] Furthermore, host and/or bacterial
factors may increase this risk, such that a high fraction of
colonized persons become infected. [18,19] For example,
a natural history study in a military population demon-
strated that soft-tissue infections occurred more fre-
quently after colonization with CA-MRSA in comparison
to methicillin-susceptible S. aureus (38% vs. 3%). [18]
Given the risk of infection associated with colonization,
particularly with CA-MRSA strains, a greater understand-
ing of the epidemiology of S. aureus colonization is
needed in order to determine optimal control and preven-
tion strategies.
Colonization with vaccine-type S. pneumoniae in the
nasopharynx has been shown to be inversely associated
with S. aureus nasal carriage in unvaccinated populations.
[20,21] This association is of particular concern given uni-
versal immunization with pneumococcal conjugate vac-
cine in the U.S. and the finding of replacement of vaccine
serotypes with non-vaccine serotypes in the nasopharynx.
[22] If vaccine serotypes do indeed interfere with coloni-
zation by S. aureus, use of PCV7 and the resulting removal
of vaccine-type pneumococci from carriage may result in
increased mucosal colonization with S. aureus.
Further elucidation of the epidemiology of S. aureus colo-
nization in young children, particularly in vaccinated
populations, and identification of risk factors for coloni-
zation is needed for the development of strategies for pre-
vention in the community. In this article we take
advantage of a unique opportunity to examine the preva-
lence and risk factors for S. aureus colonization in the con-
text of an ongoing study of nasopharyngeal
pneumococcal colonization among healthy children in
Massachusetts. Our objectives were to: (1) determine the
prevalence of S. aureus and MRSA colonization in healthy
children in the post-PCV7 era and (2) examine risk factors
for S. aureus colonization, including the absence of vac-
cine-type S. pneumoniae colonization.
Methods
Study Design and Population
We conducted a prospective observational study of S.
aureus colonization among healthy children in Massachu-
setts. [23] This study was nested within an existing study
to assess serial changes in S. pneumoniae serotypes and
antibiotic resistance in the post-PCV7 era. [24] Children 6
years and younger who were seen for either well-child care
visits or sick care visits in participating primary care prac-
tices were eligible for this study. Practices were selected
from 16 communities in Massachusetts in 2003–04 and
from 8 of these original 16 communities in 2006–07.
Each participating child was sampled, at most, once dur-
ing each swabbing season during 11/03–4/04 and 10/06–
4/07. Written informed consent was obtained from par-
ents. This study was approved by the Harvard Pilgrim
Health Care Institutional Review Board.
Parents of enrolled children completed a written survey at
the time of the visit that included information on age,
gender, race/ethnicity, history of being breastfed, child-
care attendance (>4 hours/week), smokers in the home,
family members who work in a hospital or long-term care
facility, recent antibiotic use, and history of chronic illness
in children. Dates of immunization with PCV7 and influ-
enza vaccines, diagnoses on day of visit, type of antibiotics
received in the past 2 months, and patient zip code were
obtained from medical record review. Because data on
individual household income and educational level were
not uniformly available, we used median census tract
household income and educational level from the 2000
U.S. census based on geocoding address data.
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Specimen Collection and Processing
Anterior nares swabs were collected by introducing a ster-
ile calcium alginate-tipped swab on an aluminum shaft
and gently rotating the swab. Swabs were transported by
overnight courier and processed within 24 hours. Speci-
mens were swabbed onto mannitol salt agar (MSA) plates
where they were incubated at 37°C for 48 hours. Plates
were examined for the presence of Mannitol-fermenting
colonies daily and these were subcultured to trypticase soy
agar and 5% sheep blood agar plates (BAPs) and incu-
bated at 37°C overnight. Overnight cultures on BAPs were
tested by catalase, Gram stain and Staphaurex (Remel,
Lenexa, Kansas), a rapid latex-agglutination kit for identi-
fying S. aureus. Catalase positive, Gram positive cocci
which were negative by Staphaurex were tested for coagu-
lase using rabbit plasma with EDTA. Catalase positive
Gram-positive cocci in clusters which were positive in
either the Staphaurex or coagulase tests were identified as
S. aureus and underwent sensitivity testing by either disk
diffusion or E-test for the following antibiotics: penicillin,
oxacillin, erythromycin, clindamycin, trimethoprim/sul-
famethoxazole, tetracycline, vancomycin, linezolid and
mupirocin. For erythromycin-resistant, clindamycin-sus-
ceptible isolates, a D-test was also performed to determine
the presence of erythromycin-inducible clindamycin
resistance. S. aureus isolates were considered mupirocin
resistant if the MIC was >4 μg/ml. [25] Isolation of S.
pneumoniae from NP swabs, serotyping, and antimicrobial
susceptibility testing were performed as described previ-
ously. [23]
Data Analysis
We calculated the prevalence of S. aureus and MRSA colo-
nization as a percentage with 95% confidence intervals.
When assessing trends in S. aureus colonization over time,
we compared the prevalence of colonization between
2003–04 and 2007–08 for the 8 communities participat-
ing in both sampling periods. To examine the relationship
between S. pneumoniae and S. aureus co-colonization in
individual children, we utilized data from all 16 commu-
nities. Categorical variables were compared using a chi-
square test.
To assess risk factors for S. aureus colonization, multivari-
able logistic regression models were used. Clustering
within communities was accounted for using generalized
linear mixed models. [26,27] Models of S. aureus coloni-
zation included the following variables: (1) year of swab,
individual and community-level demographic character-
istics, (2) S. pneumoniae colonization, (3) recent antibiotic
use (within 2 months), (4) breastfeeding, (5) use of child-
care outside the home, (6) diagnosis of illness on day of
swab, (7) number of doses of PCV7 received, and (8)
recent influenza vaccination. For the risk factor analyses,
data from all available communities in each sampling
period were used in our primary analyses. We also per-
formed secondary analyses limited to the 8 communities
surveyed in both periods. Because our results did not dif-
fer when analyses were limited to the 8 communities,
results from our primary analyses are presented here. All
analyses were performed using SAS version 9.1.3 (SAS
Institute, Cary, NC).
Results
Study population
One thousand nine hundred sixty-eight children were
enrolled in the study during 2003–04 and 2006–07, com-
bined. The mean (SD) age of children was 2.7 (1.8) years
with range of 0.3 to <7.0 years (Table 1). Children were
mostly white non-Hispanic (83.6%) and about half
(53.2%) lived in communities where the median annual
household income, based on U.S. census data for 2000,
was less than $55,000. Children were enrolled in at least
4 hours of childcare per week (50.7%), had smokers in the
home (19.9%), had a family member work in a hospital
or long-term care facility (17.4%), received an antibiotic
in the past 2 months (32.2%), received 3 or more doses of
PCV7 vaccine (70.6%), and received influenza vaccine in
the same season prior to their visit (24.0%).
Staphylococcus aureus colonization
14.6% (95% CI, 11.9%–17.7%) of children were colo-
nized with S. aureus in 2003–04 vs. 14.1% (95% CI,
11.9%–16.4%) in 2006–07 (p = 0.68) in the 8 communi-
ties swabbed during both periods, whereas 16.3% of chil-
dren were colonized in the 8 communities swabbed
during 2003–04 only. MRSA colonization in healthy chil-
dren remained low at 0.2% (95% CI, 0.0%–0.9%) in
2003–04 and 0.9% (95% CI, 0.4%–1.7%) in 2006–07 (p
= 0.09) for 8 communities, compared to 0.7% (95% CI
0.2%–2.1%) for the other 8 communities swabbed only
during 2003–04. Antibiotic susceptibilities for S. aureus
isolates for the 8 communities swabbed in 2003–04 and
2006–07 were as follows: penicillin (11% vs. 9%), eryth-
romycin (80% vs. 72%), clindamycin (98% vs. 80%, p <
0.001), trimethoprim/sulfamethoxazole (100% vs.
100%), tetracycline (98% vs. 98%), mupirocin (99% vs.
99%), vancomycin (100% vs. 100%), and linezolid
(100% vs. 100%) in the 8 communities swabbed during
both periods. Of these, 10 MRSA isolates were identified
with 0 susceptible to erythromycin, 4 susceptible to clin-
damycin, 9 susceptible to tetracycline, and all susceptible
to trimethoprim/sulfamethoxazole, mupirocin, vancomy-
cin and linezolid.
Staphylococcus aureus and Streptococcus pneumoniae 
colonization
Between 2003–04 and 2006–07, colonization with PCV7
strains declined (3.4% vs. 1.0%, p < 0.001) while coloni-
zation with non-PCV7 strains increased (19.4% vs.
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Table 1: Characteristics of the study population.
Total
N = 1,968)
16 communities swabbed in 2003–04
(N = 994)
8 communities swabbed in 
2006–07
(N = 974)
8 communities swabbed in 
2003–04 only
(N = 406)
8 communities swabbed in 
both seasons
(N = 588)
8 communities swabbed in 
both seasons
(N = 974)
Age group (N = 1,968)
3–<6 months 131 (6.7%) 25 (6.2%) 30 (5.1%) 76 (7.8%)
6–<12 months 299 (15.2%) 53 (13.1%) 67 (11.4%) 179 (18.4%)
1–<2 years 477 (24.2%) 100 (24.6%) 129 (21.9%) 248 (25.5%)
2–<3 years 274 (13.9%) 61 (15.0%) 82 (14.0%) 131 (13.5%)
3–<4 years 237 (12.0%) 57 (14.0%) 84 (14.3%) 96 (9.9%)
4–<5 years 231 (11.7%) 50 (12.3%) 79 (13.4%) 102 (10.5%)
5–<7 years 319 (16.2%) 60 (14.8%) 117 (19.9%) 142 (14.6%)
Female (N = 1,968) 981 (49.9%) 216 (53.2%) 308 (52.4%) 457 (46.9%)
Race/ethnicity (N = 1,872)
White non-Hispanic 1,565 (83.6%) 341 (83.9%) 463 (84.0%)20 (3.6%) 761 (82.4%)
Black non-Hispanic 86 (4.6%) 15 (3.8%) 20 (3.6%) 51 (5.5%)
Hispanic 122 (6.5%) 23 (5.8%) 28 (5.1%) 71 (7.7%)
Other 99 (5.3%) 18 (4.5%) 40 (7.3%) 41 (4.4%)
Median household income in 
community (N = 1,869)*
<40,000 373 (20.0%) 125 (31.8%) 104 (18.4%) 144 (15.8%)
40,000–<55,000 620 (33.2%) 122 (31.0%) 191 (33.9%) 307 (33.7%)
55,000–<70,000 447 (23.9%) 85 (21.6%) 135 (23.9%) 227 (24.9%)
≥70,000 429 (23.0%) 61 (15.5%) 134 (23.8%) 234 (26.7%)
% community members with <high 
school educational level (N = 1,869)*
<5% 297 (15.9%) 57 (14.5%) 79 (14.0%) 161 (17.7%)
5–<10% 387 (20.7%) 95 (24.2%) 111 (19.7%) 181 (19.9%)
10–<15% 485 (26.0%) 66 (16.8%) 164 (29.1%) 255 (28.0%)
≥15% 700 (37.5%) 175 (44.5%) 210 (37.2%) 315 (34.5%)
Ever breastfed (N = 1,900) 1,291 (68.0%) 237 (59.4%) 400 (69.8%) 654 (70.5%)
Childcare or school for ≥4 hours 
(N = 1,857)
941 (50.7%) 184 (46.8%) 296 (53.9%) 461 (50.4%)
Smokers in home (N = 1,784) 355 (19.9%) 97 (25.5%) 87 (16.1%) 171 (19.9%)
Family member works in hospital or 
LTCF (N = 1,888)
328 (17.4%) 66 (16.7%) 98 (17.5%) 164 (17.6%)
Antibiotics in past 2 months 
(N = 1,945)
Amoxicillin-clavulanate/
cephalosporins/mupirocin/TMP-
SMX
212 (10.9%) 42 (10.8%) 61 (10.5%) 109 (11.2%)
Clindamycin/macrolides 82 (4.2%) 22 (5.7%) 24 (4.1%) 36 (3.7%)
Amoxicillin/penicillin 332 (17.1%) 74 (19.0%) 86 (14.8%) 172 (17.7%)
None 1,319 (67.8%) 251 (64.5%) 411 (70.6%) 657 (67.5%)
Antibiotics in past 6 months for skin 
infection (N = 1,950)
29 (1.5%) 0 (0%) 1 (0.2%) 28 (2.9%)
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29.1%, p < 0.001) among children enrolled in the study.
No significant difference in colonization with S. aureus
was noted among those children who were and were not
colonized with S. pneumoniae. (12.4% vs. 15.5%; p =
0.10). To explore whether non-PCV7 carriage differen-
tially affected S. aureus carriage, we further examined the
proportion of people colonized with PCV7 strains vs.
non-PCV7 strains compared to those who were not colo-
nized with pneumococcus (Table 2). In children colo-
nized with PCV7 or non-PCV7 strains, 11.4% and 12.7%
were also colonized with S. aureus, respectively, compared
to 15.5% for children who were not colonized with pneu-
mococci (p = 0.29).
Risk factors for colonization
We examined risk factors for S. aureus colonization in chil-
dren <7 years (Table 3). Bivariate analyses revealed that
age had a U-shaped relationship with S. aureus coloniza-
tion, with increased colonization among children <6
months and 5–<7 years. S. aureus colonization was lowest
among children 1–<2 years of age. Use of antibiotics in
the past 2 months was also associated with lower risk of S.
aureus colonization. When the type of antibiotics used in
the past 2 months was considered, we found that the
inverse relationship with S. aureus colonization remained
regardless of whether the antibiotic was very likely (amox-
icillin-clavulanate, cephalosporins, mupirocin, trimetho-
prim-sulfamethoxazole), somewhat likely (clindamycin,
macrolides), or unlikely (amoxicillin, penicillin) to have
clinical activity against S. aureus.
In multivariable models, age and antibiotic use in the past
2 months remained significantly associated with S. aureus
colonization when adjusted for other individual and com-
munity-level demographic characteristics and S. pneumo-
niae colonization (Table 4). Children 6 months-<1 year,
1–<2 years, 2–<3 years, and 3–<4 years of age were signif-
icantly less likely to be colonized with S. aureus compared
to children 5 years and older. Also, children who recently
received antibiotics in the past 2 months were less likely
to be colonized with S. aureus. The addition of other pre-
dictors such as breastfeeding, childcare use, diagnosis on
History of chronic illness
Asthma/RAD (N = 1,950) 199 (10.2%) 27 (6.9%) 80 (13.7%) 92 (9.5%)
Skin condition† (N = 974) 47 (4.8%) - - 47 (4.8%)
Diagnosis on day of visit (N = 1,950)
Asthma/RAD 73 (3.7%) 18 (4.6%) 19 (3.3%) 36 (3.7%)
Rash 65 (3.3%) 9 (2.3%) 12 (2.1%) 44 (4.5%)
Otitis media 258 (13.2%) 30 (7.7%) 61 (10.5%) 167 (17.2%)
Respiratory tract infection 461 (23.6%) 76 (19.4%) 95 (16.3%) 290 (29.8%)
Skin/soft tissue infection 14 (0.7%) 0 (0%) 1 (0.2%) 13 (1.3%)
Allergic rhinitis/seasonal allergies 13 (0.7%) 3 (0.8%) 7 (1.2%) 3 (0.3%)
Colonization with Streptococcus 
pneumoniae (N = 1,964)
524 (26.7%) 91 (22.4%) 141 (24.0%) 292 (30.1%)
Pneumococcal vaccination** 
(N = 1,950)
0 doses 209 (10.7%) 76 (19.4%) 113 (19.4%) 20 (2.1%)
1 dose 170 (8.7%) 40 (2.1%) 61 (3.1%) 69 (7.1%)
2 doses 194 (10.0%) 38 (9.7%) 82 (14.0%) 74 (7.6%)
3 doses 1377 (70.6%) 238 (60.7%) 328 (56.2%) 811 (83.3%)
Influenza vaccination prior to visit††
(N = 1,950)
467 (24.0%) 65 (16.6%) 45 (7.7%) 357 (36.7%)
*Household income and educational level based on geocoded information from 2000 U.S. census.
† Assessed in 2007–08 season only
** Pneumococcal dose included if given at least 30 days prior to swab
†† Flu vaccination in that season at least 2 weeks prior to visit
Table 1: Characteristics of the study population. (Continued)
Table 2: Streptococcus pneumoniae and Staphylococcus aureus 
colonization.
S. aureus colonization
No Yes
PCV7 strains 39 (88.6%) 5 (11.4%)
Non-PCV7 strains 414 (87.3%) 60 (12.7%)
No S. pneumoniae colonization 1217 (84.5%) 223 (15.5%)
Total 1670 (85.3%) 288 (14.7%)
Unadjusted p-value = 0.29
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Table 3: Proportion colonized with Staphylococcus aureus and bivariate predictors of colonization adjusted for clustering by 
community
% colonized Bivariate OR
(95% CI)
P-value
Year of Swab (N = 1,968) 0.43
2003–04 15.3% 1.0
2006–07 14.1% 0.90 (0.70–1.17)
Age group (N = 1,968) <0.001
<6 months 16.8% 0.59 (0.35–1.00)
6–<12 months 10.7% 0.36 (0.23–0.55)
1–<2 years 9.4% 0.31 (0.21–0.46)
2–<3 years 12.0% 0.40 (0.26–0.63)
3–<4 years 13.9% 0.47 (0.30–0.74)
4–<5 years 18.6% 0.68 (0.45–1.03)
≥5 years 25.4% 1.0
Female (N = 1,968) 13.7% vs. 15.7% 0.85 (0.66–1.09) 0.20
Race/ethnicity (N = 1,872) 0.85
White non-Hispanic 14.3% 1.0
Black non-Hispanic 16.3% 1.15 (0.64–2.08)
Hispanic 15.6% 1.08 (0.65–1.80)
Other 12.1% 0.81 (0.44–1.51)
Median household income in community (N = 1,869) 0.76
<$40,000 12.9% 0.83 (0.54–1.27)
$40,000–$54,999 15.3% 1.01 (0.70–1.45)
$55,000–$69,999 14.1% 0.92 (0.62–1.35)
≥$70,000 15.4% 1.0
% community members with <high school educational level (N = 1,869) 0.74
<5% 16.2% 1.10 (0.74–1.64)
5–<10% 13.4% 0.88 (0.61–1.28)
10–<15% 13.8% 0.92 (0.66–1.29)
≥15% 15.0% 1.0
Ever breastfed (N = 1,900) 14.5% vs. 14.6% 0.99 (0.75–1.30) 0.94
Childcare or school for ≥4 hrs (N = 1,857) 15.7% vs. 13.1% 1.24 (0.95–1.60) 0.11
Smokers in home (N = 1,784) 15.5% vs. 13.8% 1.16 (0.83–1.60) 0.39
Family member works in hospital or long-term care facility (N = 1,888) 11.9% vs. 15.0% 0.76 (0.53–1.09) 0.14
Antibiotics in past 2 months (N = 1,945) <0.001
Amoxicillin-clavulanate/cephalosporins/mupirocin/TMP-SMX 8.0% 0.42 (0.25–0.71)
Clindamycin/macrolides 9.8% 0.51 (0.24–1.08)
Amoxicillin/penicillin 10.5% 0.57 (0.39–0.83)
No antibiotics 17.1% 1.0
Antibiotics in past 6 months for a skin infection (N = 1,950) 10.3% vs. 14.7% 0.67 (0.20–2.22) 0.51
History of chronic illness (N = 1,950)
Asthma/RAD (N = 1,950) 17.6% vs. 14.3% 1.29 (0.88–1.91) 0.20
Skin condition (N = 974) 17.0% vs. 13.9% 1.27 (0.58–2.78) 0.55
Diagnosis on day of visit (N = 1,950)
Asthma/RAD 20.6% vs. 14.3% 1.57 (0.88–2.81) 0.13
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day of swab, pneumococcal colonization, number of
doses of PCV7 vaccine, and recent influenza vaccination
did not change the results of our model. Thus, we present
the most parsimonious model in Table 4. Because the
number of MRSA isolates was small (N = 13) in our pop-
ulation, we did not examine risk factors for MRSA coloni-
zation.
Discussion
Between 2003–04 and 2006–07, S. aureus (15.3% to
14.1%) and MRSA (0.4% to 0.9%) colonization of the
nares among children 3 months to <7 years remained sta-
ble in the setting of widespread use of the pneumococcal
conjugate vaccine in Massachusetts and decreasing coloni-
zation with PCV7 strains. [28] Although S. aureus coloni-
zation was lower among children who were
concomitantly colonized with S. pneumoniae, this rela-
tionship was modest and not statistically significant. Pre-
vious studies that found a negative association between
these two species documented that the relationship was
strongest when limited to S. pneumoniae serotypes
included in the pneumococcal conjugate vac-
cine[20,21,29,30] and when limited to MRSA. [29] The
lack of statistical significance in our study may be due to
the relative rarity of PCV7 serotypes among pneumococci
and MRSA among S. aureus isolates in our population.
The prevalence of S. aureus colonization in young children
in Massachusetts is lower than has previously been
reported by NHANES (36% among 1–19 year olds),
although MRSA colonization in Massachusetts is similar
to national estimates (0.9% among 1–19 year olds) from
2001–04. [3] Other cross-sectional studies have found
prevalence rates for S. aureus and MRSA, ranging from
18.9% to 24.4% and 0.6% to 1.7%, respectively. [31,32]
In contrast to our findings, a serial cross-sectional study of
nasal carriage among young healthy children conducted
in other settings found a rising prevalence of both S.
aureus (29% to 36%) and MRSA (0.8% to 9.2%) coloniza-
tion from 2001 to 2004. [33,34] Unlike our study, how-
ever, little was known about the potential impact of
changing pneumococcal colonization patterns due to
PCV7 use on carriage of S. aureus and MRSA.
Between 2003–04 and 2006–07, S. aureus isolates
remained susceptible to trimethoprim/sulfamethoxazole,
tetracycline, mupirocin, vancomycin and linezolid in 8
communities. However, a smaller proportion of isolates
were susceptible to erythromycin and clindamycin in the
latter season. Interestingly, antibiotic dispensing for
broad-spectrum macrolides, such as clarithromycin and
azithromycin, in a similar set of communities in Massa-
chusetts has increased over a similar time period. [35] It is
plausible that antibiotic pressure in these communities
may have contributed to the emergence of strains such as
USA300 with this particular antibiotic resistance pheno-
type. [36-38]
In multivariate models, S. aureus colonization was found
to be age-dependent in agreement with other published
studies. [20,32,33,39] Recent use of antibiotics was also
found to be inversely associated with S. aureus coloniza-
tion similar to prior studies. [39,40] Although we found
reduced S. aureus colonization following antibiotic use,
we may only be seeing a transient decline in S. aureus col-
onization without fully understanding the longer-term
impact of antibiotic use and the emergence of resistant
organisms, since our study was cross-sectional in design.
[41,42] Furthermore, we found that colonization with S.
aureus was lower in children regardless of the type of anti-
biotic used. This relationship is intriguing since we postu-
lated that only antibiotics clinically active against S. aureus
would be inversely associated with colonization as sug-
gested by prior published studies. [39] One possibility is
that recent antibiotic use is associated with another char-
acteristic of these individuals that we were not able to
Rash 21.5% vs. 14.4% 1.66 (0.91–3.03) 0.10
Otitis media 12.0% vs. 15.0% 0.77 (0.52–1.14) 0.19
Respiratory tract infection 16.5% vs. 14.0% 1.20 (0.90–1.59) 0.22
Skin/soft tissue infection 7.1% vs. 14.7% 0.43 (0.06–3.29) 0.42
Allergic rhinitis/seasonal allergies 7.7% vs. 14.7% 0.48 (0.06–3.70) 0.48
Colonization with Streptococcus pneumoniae (N = 1,964) 12.4% vs. 15.5% 0.78 (0.58–1.05) 0.10
Pneumococcal vaccination (N = 1,950) 0.08
0 doses 19.6% 1.0
1 dose 17.7% 0.87 (0.52–1.47)
2 doses 13.9% 0.67 (0.39–1.14)
3+ doses 13.6% 0.64 (0.44–0.93)
Influenza vaccination prior to visit (N = 1,950) 12.4% vs. 15.3% 0.78 (0.57–1.06) 0.11
Table 3: Proportion colonized with Staphylococcus aureus and bivariate predictors of colonization adjusted for clustering by 
community (Continued)
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measure. It may also be possible that part of the decline is
due in part to 11% of the circulating S. aureus isolates in
our population being susceptible to penicillins. The
impact of recent antibiotic use on colonization patterns
will be an important area for further study given concerns
over the competitive balance between organisms in the
nasopharynx. [43].
There are several potential limitations to our study. First,
we only included children less than 7 years of age, who
may be at lower risk for MRSA colonization than older
children. Second, we did not adequately assess all sites of
colonization (e.g. skin, throat, rectum), thus underesti-
mating the true prevalence of MRSA colonization, partic-
ularly since community-associated MRSA may be more
likely than other MRSA or MSSA strains to colonize non-
nasal sites. [44] Third, we did not use an enrichment broth
to isolate S. aureus or MRSA, which may have enhanced
detection rates in other studies. Fourth, we only swabbed
healthy children in Massachusetts, which is one of the last
geographic areas to be hit by the CA-MRSA epidemic. [45]
In contrast, significant increases in CA-MRSA disease and
colonization have occurred in other parts of the country
between 2003–04 and 2006–07. [11,12,31-34,37,46-49]
Finally, we did not swab children longitudinally; thus, we
were not able to assess whether these risk factors were dif-
ferent for children with transient vs. persistent S. aureus
carriage.
Table 4: Multivariate predictors of Staphylococcus aureus colonization adjusted for clustering by community (N = 1,707)
Multivariable OR (95% CI) P-value
Year of swab 0.71
2003–04 1.0
2006–07 0.95 (0.71–1.26)
Age group <0.001
<6 months 0.61 (0.34–1.08)
6–<12 months 0.39 (0.24–0.64)
1–<2 years 0.35 (0.23–0.54)
2–<3 years 0.45 (0.28–0.73)
3–<4 years 0.53 (0.33–0.86)
4–<5 years 0.70 (0.44–1.11)
≥5 years 1.0
Female 0.83 (0.63–1.10) 0.20
Race/ethnicity 0.99
White non-Hispanic 1.0
Black non-Hispanic 0.96 (0.49–1.90)
Hispanic 0.95 (0.51–1.76)
Other 0.90 (0.46–1.77)
Median household income in community 0.89
<$40,000 0.99 (0.51–1.93)
$40,000–$54,999 1.14 (0.67–1.94)
$55,000–$69,999 1.11 (0.67–1.84)
≥$70,000 1.0
% community members with <high school educational level 0.65
<5% 0.99 (0.53–1.87)
5–<10% 0.76 (0.45–1.27)
10–<15% 0.87 (0.57–1.32)
≥15% 1.0
Colonization with Streptococcus pneumoniae 0.92 (0.67–1.27) 0.62
Antibiotics in past 2 months 0.005
Amoxicillin-clavulanate/cephalosporins/mupirocin/TMP-SMX 0.57 (0.33–0.97)
Clindamycin/macrolides 0.51 (0.24–1.08)
Amoxicillin/penicillin 0.54 (0.35–0.84)
No antibiotics 1.0
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Conclusion
We conclude that S. aureus and MRSA colonization of the
nares remained stable from 2003–04 to 2006–07 among
children less than 7 years in Massachusetts communities
despite widespread use of pneumococcal conjugate vac-
cine during these time periods. S. aureus nasal coloniza-
tion varies by age and appears inversely correlated with
recent antibiotic use. Continued monitoring of the ecol-
ogy of colonization patterns among children will be
essential to improve our understanding of risk for disease
due to S. aureus and MRSA in the community.
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